Analysis reveals that T-cell malignancies accounted for 0.1% of reports submitted to FDA following CAR T-cell therapy   (WASHINGTON, March 14, 2024) – An analysis published today in Blood found that secondary cancers following C...

Study suggests optimal therapy may differ for pre-existing versus new-onset hypertension (WASHINGTON, Feb. 5, 2024) – Combination treatments with two or more blood pressure drugs can significantly reduce blood pressure in patients taking ibrutinib, a...

First of its kind study evaluates liso-cel cost effectiveness through societal costs and benefits. (WASHINGTON, Dec. 28, 2023) – Lisocabtagene maraleucel (liso-cel), a CAR T-cell therapy, is a cost effective second line treatment for relapsed and re...

Findings show children with underlying medical conditions are at heightened risk, highlight importance of physical activity to prevent most common complications.  (WASHINGTON, Dec. 26, 2023) – In the first study to comprehensively examine...

ASH Research Collaborative Publishes Preliminary Results of Largest Prospective mRNA Vaccine Efficacy Trial in Individuals with SCD to Date (SAN DIEGO, Dec. 12, 2023) – New research presented by the ASH Research Collaborative (ASH RC) dur...

Ibrutinib-venetoclax combination shows superior progression-free survival and higher complete response rate than ibrutinib and placebo LBA-2: Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analys...

The single-drug therapy provides clinical benefit and could help more patients with hard-to-treat leukemias proceed to stem cell transplant LBA-5: Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy...

First head-to-head comparison supports adding daratumumab to standard frontline regimen LBA 1: Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed...

Less Toxic Approach to Haploidentical Bone Marrow Transplantation in Adults Living with Severe Sickle Cell Disease Offers Promise  LBA-4: Reduced Intensity Haploidentical Bone Marrow Transplantation in Adults with Severe Sickle Cell Disease: BMT...

The award recognizes elected officials who have led legislation related to hematology research and practice (SAN DIEGO, Dec. 10, 2023) – The American Society of Hematology (ASH) will honor Sen. Chris Van Hollen (D-MD) for his outstanding suppor...